Placeholder Banner

BIO Submits Comments on CDC Clinical Practice Guideline for Prescribing Opioids

April 11, 2022

On Monday, April 11th, BIO also submitted comments in response to the CDC’s recently published Clinical Practice Guideline for Prescribing Opioids. In the comments submitted, BIO primarily requested that the CDC revise its language referencing naloxone to be consistent with more general and product agnostic references, e.g., FDA-approved opioid overdose reversal medication.

Download Full Comments Below
BIO COMMENT LETTER CDC Guideline for Prescribing Opioids
Discover More
The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments regarding the request and comments on the Advanced Manufacturing Technologies Designation Program Draft Guidance.
The Biotechnology Innovation Organization thanks the Food and Drug Administration for the opportunity to submit comments regarding the request for information and comments on the Food and Drug Administration's Draft Report and Plan on Best Practices…
Following the FDA Workshop to Enhance Clinical Study Diversity on November 29-30, 2023, BIO submits specific comments per the request for information (FDA-2023-N-2462).